Novo Nordisk A S (NVO $47.08 -8.78%) is steering through the sharpest growth-rate reversal in its GLP-1 franchise since the launch of Ozempic. The Q1 2026 interim report shows US Operations adjusted sales down 11% at CER on lower realised prices, with the company guiding adjusted sales growth to -4% to -12% at CER for the full year even after the Wegovy oral pill's January launch cleared 200,000 weekly TRxs by mid-April. The setup is whether the announced 1 January 2027 WAC cut to USD 675 and the MFN rebate structure buy a defended volume base, or whether realised prices compound lower as the channel mix shifts further to cash-pay and Medicare Part D reform draws more script volume onto sub-list economics.
The volume defence is real but narrowly won: the Wegovy pill's first-quarter prescription count of around 1.3 million, per the same Q1 2026 disclosure, marks the strongest-ever GLP-1 volume launch in the US by that measure, with total weekly prescriptions for injectable Wegovy at around 270,000 for the week ending 17 April 2026. Pricing is the variable doing the compensating. Management's framing on the Q4 2025 call was that price reduction is in some ways our investment for the future and for capturing more patients rather than a passive concession, and the MFN deal plus the WAC reset are the explicit expression of that view.
The contested claim: Novo Nordisk can grow the Wegovy pill into a defended base large enough to offset the realised-price compression baked into the 2026 guide, and the 1.3 million Q1 prescriptions are the first concrete datapoint that base is forming, not just a launch artefact.
The data behind this piece
Every figure above comes from NVO’s filings. Open the source pages:
Market scepticism on growth is overstating the volume base that has already formed
Price performance vs peers (Drug Manufacturers - General)
| Company | Last close | 52-week change | 52-week high | Off 52-week high |
|---|---|---|---|---|
| Novo Nordisk A S | $51.61 | +3.2% | $63.98 | -19.3% |
| ELI LILLY & Co | $1154.97 | +52.0% | $1235.56 | -6.5% |
| Johnson & Johnson | $255.82 | +52.9% | $267.24 | -4.3% |
| AbbVie Inc. | $257.41 | +36.0% | $263.30 | -2.2% |
| Merck & Co., Inc. | $129.79 | +58.8% | $131.82 | -1.5% |
The headline read on the price-performance table groups Novo Nordisk A S with the weakest tape in the GLP-1 bellwether set: a last close of $51.61 against a 52-week move of +3.2% sits well behind Eli Lilly (LLY $1,148.84 -0.53%) at +52.0%, Johnson & Johnson (JNJ $256.35 +0.21%) at +52.9%, AbbVie (ABBV $250.94 -2.51%) at +36.0% and Merck (MRK $130.20 +0.32%) at +58.8%. The print is still well below the 52-week high of $63.98, a roughly one-fifth drawdown. None of the four US peers is more than 6.5% off its high. The market is therefore pricing Novo Nordisk as the structurally impaired name in the cohort, not a laggard catching up.
That positioning sits against a dividend stream that has not been cut. The four most recent US-dollar distributions per ADS, $1.275 (2026-03-30), $0.584 (2025-08-18), $1.099 (2025-03-31), $0.513 (2024-08-16), pair an interim and a final each year, with the March payments stepping up from $1.099 to $1.275 and the August payments from $0.513 to $0.584. The recurring interim-plus-final structure is intact even as the stock rerates, though the US-dollar step-ups from $1.099 to $1.275 and from $0.513 to $0.584 reflect the 2.6% per-share increase and DKK/USD movement rather than a like-for-like US-dollar payout trajectory.
The volume defence underwriting that rerating sits in the brief, not in the price tape. Wegovy pill TRxs of around 1.3 million in Q1 2026, with weekly prescriptions exceeding 200,000 by mid-April, are the strongest GLP-1 launch on that measure per the Q1 2026 interim report. The 2026 adjusted-sales guide of -4% to -12% at CER is the cost of converting that volume under the MFN deal.
Management tone: defended volume, explicit price reset, no supply constraint
Novo Nordisk's leadership frames 2026 as a year of pricing headwinds the company is buying into. CEO Maziar Doustdar told the Q4 2025 call that 2026 will be basically a year where we will face some headwinds, especially on the back of the price declines, and described price reduction as the company's investment for the future. CFO Karsten Knudsen characterised the US decline as driven by price declines, from both cash-channel investments at a different price point and the MFN impact, framing the deal as roughly double on US operations while only a low single-digit hit at the group level. Q1 2026 commentary carried the same posture: the interim report attributes the adjusted-sales decline to lower realised prices, partly offset by GLP-1 volume growth.
Peer management teams are not seeing the same dynamic. Eli Lilly CEO David Ricks told the Q1 2026 call that Lilly delivered 56% revenue growth in the first quarter, and CFO Lucas Montarce said prices has been relatively stable quarter on quarter, citing the November MFN agreement and NRDL access as the components already absorbed. Lilly's product detail remains expansionary: Mounjaro more than doubled, Zepbound grew roughly four-fifths, and Zepbound still held around 70% of branded obesity new prescriptions per the Q4 2025 call. Lilly is investing to compete, not defending volume.
Johnson & Johnson is on a different cycle entirely. CEO Joaquin Duato said on the Q1 2026 call that J&J is on track to meet its 2026 target of $100 billion in annual revenue for the first time and reaffirmed line of sight to double-digit growth by the end of the decade, anchored by DARZALEX (called the #1 product with sales of $4 billion and operational growth of 18%) and TREMFYA (called up 64%). The bear case for J&J is a known and shrinking item: STELARA biosimilar drag is flagged in the H1 2026 10-Q as a quantifiable headwind that management is guiding over, not around.
AbbVie's management is reaffirming long-term growth while absorbing the proposed Apogee deal. Chairman and CEO Robert A. Michael said on the Q2 2026 release that AbbVie delivered another excellent quarter with substantial momentum. The Q2 8-K disclosed the Apogee acquisition is expected to be $0.14 dilutive in 2026, partially offset by $0.10 of overperformance, leaving the full-year adjusted EPS guide unchanged in dollar terms but tighter. Skyrizi and Rinvoq both grew around a quarter in the quarter per the Q2 8-K, the portfolio is compounding, and capital return ran at $1.1 billion of buybacks in Q1 2026 with a $1.73 quarterly dividend held flat.
Merck's tone is the cleanest read of a company raising guidance through the year. CEO Rob Davis told the Q1 2026 call that Merck delivered year-over-year growth with revenue of $16.3 billion, driven by continued strength in oncology, animal health, and growing contributions from new products. CFO Caroline Litchfield narrowed the FY2026 sales range to $65.8–$67.0 billion (from $65.5–$67.0 billion at Q4 2025) and the non-GAAP EPS range to $5.04–$5.16 (from $5.00–$5.15), citing roughly 1% positive FX in both. The cadence of guidance changes, raise the midpoint, narrow the range, keep the same destination, is the opposite of Novo Nordisk's, which raised the midpoint by tightening the range while the destination sits in negative territory.
The peer set splits cleanly. Lilly, J&J, AbbVie and Merck are all managing to volume-led growth with pricing as a footnote. Novo Nordisk is the only name in the cohort guiding negative adjusted-sales growth for the year, and management is saying so explicitly.
Wegovy pill volume and MFN pricing reset redefine the growth scoreboard
Performance vs peers (Drug Manufacturers - General)
| Company | Market cap | Last close | YTD return | Revenue growth (YoY) | Short interest (% of shares) |
|---|---|---|---|---|---|
| Novo Nordisk A S | $228.2B | $51.61 | +5.2% | — | 0.7% |
| ELI LILLY & Co | $1.1T | $1154.97 | +7.7% | +44.7% | 1.1% |
| Johnson & Johnson | $616.5B | $255.82 | +24.3% | +6.0% | 1.1% |
| AbbVie Inc. | $454.8B | $257.41 | +13.6% | +8.6% | 1.3% |
| Merck & Co., Inc. | $320.6B | $129.79 | +25.1% | +1.4% | 1.2% |
The scoreboard Novo Nordisk's own disclosures put forward is dominated by the Wegovy pill and the realised-price reset, not by the legacy GLP-1 base. The Q1 2026 interim report records Wegovy pill US sales of DKK 2,256 million in the quarter, "impacted by pre-launch pipeline fill with wholesalers and telehealth partners", a figure that flags the launch ramp rather than steady-state demand. Total weekly Wegovy pill TRxs exceeded 200,000 for the week ending 17 April 2026, with total pill prescriptions of around 1.3 million in Q1 2026 and more than 2 million since launch — the strongest-ever GLP-1 volume launch in the US on that measure. Injectable Wegovy added around 270,000 weekly TRxs for the same week, of which around 100,000 were filled in the self-pay channel via retail and NovoCare Pharmacy including telehealth organisations. Total obesity-care sales reached DKK 31 billion in 2025, with Wegovy sales of DKK 28 billion growing 134% per the Q4 2025 call.
The price scoreboard runs the other way. The same Q1 2026 report records US Operations adjusted sales down 11% at CER, driven by lower realised prices, and an adjusted gross margin of 80.6% versus 83.5% in 2025. The pricing reset is explicit: effective 1 January 2027, the WAC on Wegovy injection 2.4 mg and 7.2 mg, Wegovy tablets up to 25 mg, Ozempic injection 0.5 mg, 1 mg and 2 mg, and Ozempic pill tablets 7 mg or 14 mg moves to USD 675: reductions of approximately 50% and 35% from the current list price for Wegovy and Ozempic respectively. Self-pay prices already range from USD 149–299 per month by dose. The 2026 outlook itself anchors the trajectory: adjusted sales growth of -4% to -12% at CER, with the improvement versus the prior -5% to -13% range driven by increased expectations for GLP-1 product sales, and the 80.6% gross margin already inside 2025.
The capital-return scoreboard is intact in DKK terms: total cash returns of DKK 37.7 billion in Q1 2026 (DKK 2.4 billion share buybacks plus DKK 35.3 billion dividends), with a 2025 proposed total dividend of DKK 11.70 per A/B share, a 2.6% increase per the Q4 2025 call. The four US-dollar distributions per ADS shown above pair an interim and a final each year, with the March payments stepping from $1.099 to $1.275 and the August payments from $0.513 to $0.584, a recurring structure preserved through the rerating.
Against the peer set, the scoreboard looks one-sided. The price-performance table shows Novo Nordisk at +3.2% over 52 weeks and 19.3% off its high, while Eli Lilly sits at +52.0% and 6.5% off, Johnson & Johnson at +52.9% and 4.3% off, AbbVie at +36.0% and 2.2% off, and Merck at +58.8% and 1.5% off. Lilly, J&J, AbbVie and Merck are all guiding to positive growth; Novo Nordisk is the only name in the cohort guiding negative adjusted-sales growth for the year, and management is saying so explicitly.
Adjacent reporters see the same volume, but only Novo Nordisk is guiding down
Eli Lilly, the direct GLP-1 share-taker, said on the Q1 2026 call that US incretin analog obesity prescriptions grew more than 80% and self-pay accounted for around 45% of total Zepbound prescriptions in Q1. Lilly's same filing carried US realised-price declines of -7% on Mounjaro and Zepbound in Q1 and a low- to mid-teens guide for 2026 price erosion. The transmission is plain: the same demand pool is being filled by both incumbents, and the same pricing reset is hitting both books. Lilly's Mounjaro grew 125% and Zepbound 80% in Q1 2026 even with that price drag, which puts Wegovy pill Q1 TRxs in context as a launch artefact of a category rather than a single-firm distortion. The implication for Novo Nordisk is conditional: if the MFN-and-channel-mix reset is the industry-wide cost of the volume, the Wegovy pill base scales with the category rather than against it, but the realised-price compression does not unwind because Lilly accepts it too.
The three wholesalers carrying 23%, 18% and 14% of Novo Nordisk's 2025 global net sales, McKesson, Cencora and Cardinal Health, all report GLP-1-led volume in their most recent quarters. Cencora's Q2 FY26 release said US growth was driven by unit volume growth including products labeled for diabetes and/or weight loss in the GLP-1 class, with the offset being that GLP-1s carry lower gross profit margins for the distributor. Cardinal Health's Q3 FY26 8-K showed Pharmaceutical and Specialty Solutions segment profit up 18%, and McKesson's Q4 FY26 release reported North American Pharmaceutical prescription-volume growth partly offset by lower branded contributions. The read for Novo Nordisk is direct: the channel is absorbing the volume, and the gross-margin hit lives at both ends of the pipe. If wholesaler commentary softens, that is the early signal that the cash-channel ramp is plateauing.
The threat on the supply side is competitor launches rather than input costs. Amgen expanded the MariTide Phase 3 program at Q1 2026 including a switch study from weekly tirzepatide or semaglutide, and Pfizer/Sciwind launched ecnoglutide in China on 27 April 2026 per Pfizer's Q1 2026 release. If MariTide reads out and ecnoglutide internationalises, the Wegovy pill's first-mover base competes from year two, not from launch.
Capital return absorbs the operating cash without leverage pressure
Novo Nordisk's Q1 2026 interim report shows total equity of DKK 203,065 million, equivalent to 36.3% of total assets at the end of March 2026, compared with 35.7% at the end of 2025. Capital returned to shareholders in the first three months of 2026 was DKK 37.7 billion, split between DKK 2.4 billion of share buybacks and DKK 35.3 billion of dividends, against an operating quarter that funded a capital expenditure programme of DKK 11.3 billion for property, plant and equipment.
The buyback programme frames the run-rate. As of 4 May 2026, Novo Nordisk had repurchased 14,759,179 B shares for DKK 3,799,999,990 under the up-to-DKK 15 billion programme running from 4 February 2026. A new programme of up to DKK 11,200,000,010.45 was initiated 6 May 2026 for execution through 1 February 2027. By 24 July 2026, the cumulative buyback since 4 February 2026 had reached 25,919,179 B shares at an average price of DKK 276.33 per B share, a transaction value of DKK 7,162,368,893 per the most recent 6-K. The buyback is being executed against a 2026 free cash flow guide of DKK 36–46 billion, comfortably inside the cash envelope.
Management's stance on the dividend is unchanged: the Q4 2025 call framed total 2026 cash returns as anticipated to be over DKK 60 billion, with the 2025 proposed total dividend of DKK 11.70 per share marked as the 30th consecutive year of increase at 2.6%. The peer picture from the same calls and filings shows AbbVie's quarterly dividend held at $1.73 through 2026 with $1.1 billion repurchased in Q1, J&J running its 64th consecutive year of dividend growth at $5.36 annualised with H1 2026 dividends of $2.64 per share, Merck at $0.85 per quarter (up from $0.81), and Eli Lilly at $1.73 paid per share in Q1 with $2.4 billion of repurchases. Novo Nordisk's payout is the largest in absolute DKK terms but the leverage ratio is what funds it: equity at 36.3% of total assets leaves the balance sheet able to absorb the 2026 guide without further debt issuance.
The Wegovy pill base has to scale under a 50% WAC cut and a price-everywhere reset
The Wegovy pill base has to convert launch artefacts into retained patients. The Q1 2026 disclosure put the count at around 1.3 million Q1 TRxs and more than 2 million since launch; that number needs to keep growing because the 2026 adjusted-sales guide of -4% to -12% at CER is built on volume offsetting realised-price compression, not on price stabilising. If the cash-channel ramp plateaus ahead of Medicare Part D's 1 July 2026 pilot, the guided band goes the other way.
Self-pay economics have to hold as the WAC resets. Wegovy injectable 7.2 mg and 2.4 mg, Wegovy tablets up to 25 mg, Ozempic injectable 0.5/1/2 mg, and Ozempic pill 7/14 mg move to a USD 675 list price effective 1 January 2027 — reductions of roughly 50% on Wegovy and 35% on Ozempic per the Q1 2026 interim report. The USD 149–299 monthly self-pay band already exists, so the WAC cut mostly reprices the commercial and Medicare books. Realised gross margin has to defend 80.6% against the further mix shift toward sub-list economics that the MFN deal formalises.
International Operations has to keep absorbing the price compression. Q1 2026 International Operations sales grew 6% at CER while US Operations fell 11%; semaglutide generics have launched in India and have been approved in Canada per the same filing, with loss of exclusivity flagged as a 2026 sales headwind. If generic penetration accelerates beyond what is already in the guide, the international growth offset shrinks and the consolidated band widens toward -12%.
Capital return has to stay inside DKK 36–46 billion of guided free cash flow. Q1 2026 returned DKK 37.7 billion (DKK 2.4 billion buybacks plus DKK 35.3 billion dividends), the 2025 dividend was raised 2.6% to DKK 11.70 per the Q4 2025 call, and a fresh DKK 11.2 billion buyback programme began 6 May 2026. If the free cash flow band compresses under heavier realised-price erosion, the dividend trajectory, 30 consecutive years of increase, is the line most exposed.
Competitor launches have to stay behind the oral wave. Eli Lilly's orforglipron approved in Q1 2026, Pfizer/Sciwind's ecnoglutide launched in China on 27 April 2026 per Pfizer's Q1 2026 release, and Amgen's MariTide Phase 3 expanded to include a switch study from weekly tirzepatide or semaglutide. If a MariTide readout hits before Wegovy pill scale locks in, the first-mover base erodes.
The bear case lives in the same evidence: if realised prices compound lower because the cash-channel mix continues to migrate, if generics penetrate International Operations faster than the guide assumes, or if a competitor reaches the US obesity market ahead of scale, the Wegovy pill base defends a smaller franchise than the launch currently implies.
Risk/reward
The earlier sections established a wide guided band: adjusted sales growth of -4% to -12% at CER, free cash flow of DKK 36-46 billion, and a US tape that is the weakest in the bellwether set at +3.2% over 52 weeks and roughly one-fifth off the $63.98 high. The bull case rests on a single number from the Q1 2026 interim report: Wegovy pill TRxs of around 1.3 million in Q1 2026 and more than 2 million since launch, with total weekly prescriptions exceeding 200,000 by mid-April. The bear case rests on the same filing: US Operations adjusted sales down 11% at CER, adjusted gross margin at 80.6% versus 83.5%, and a 1 January 2027 WAC cut of roughly 50% on Wegovy and 35% on Ozempic that locks in further realised-price compression. The volume base is forming; the price reset is mandatory.
Bull scenario, bounded by the evidence: the Wegovy pill TRx base compounds through 2026 inside the MFN structure, and the 2026 adjusted-sales guide lands at the favourable -4% end as the cash-channel ramp and the Medicare Part D pilot starting 1 July 2026 absorb the WAC cut. Free cash flow prints toward DKK 46 billion, the up-to-DKK 15 billion buyback and the DKK 11.7 billion 2025 dividend per A/B share are funded, and the multiple re-rates toward peers.
Bear scenario, bounded by the evidence: realised prices compound lower as the channel mix migrates further, semaglutide generics in India and approved in Canada widen the international drag, and a competitor reads out before pill scale locks in. The guide lands toward -12%, free cash flow compresses toward DKK 36 billion, and the DKK 11.2 billion second buyback tranche initiated 6 May 2026 absorbs most of the buyback envelope. The drawdown from the $63.98 high extends, and the 80.6% gross margin, already down from 83.5%, gives back further.
The evidence supports the bear direction. The guide is negative while four US peers guide to positive operational growth, and the WAC reset has not yet flowed through reported sales. The Wegovy pill volume datapoint is the one item the bear cannot yet refute, and it is what a reader should monitor next: the Q2 2026 6-K for sustained TRx growth, the 1 January 2027 WAC implementation, Medicare Part D pilot uptake from 1 July 2026, and any MariTide or orforglipron commercial readouts.
Data comes from SEC filings, earnings-call transcripts and Equibles' deterministic datasets; the commentary is from earnings-call transcripts and filings gathered by Equibles research agents. This article is for information only and is not investment advice.